The grocery store formerly known as Steve’s 9th Street Supermarket in Park Slope has a new occupant. K Slope Market, a full-service supermarket and member of the Key Food Cooperative, opened its doors ...

In this handout photograph taken and released by the Ukrainian Presidential Press Service on November 18, 2024, a motorcade carrying Ukrainian president drives past a road sign marking the entrance to ...

A third attempt by students at Point Loma Nazarene University in San Diego to establish a school-supported Turning Point USA (TPUSA) chapter was denied by the university's Associated Student Body (ASB ...

Outraged voters and politicians alike are demanding to know why a group of Senate Democrats sided with Republicans to reopen the government without securing any concessions on preserving health care ...

Once again, Israeli bombs rained down on Gaza. The latest wave of strikes killed more than 100 people, mostly women and children, according to health authorities. The bombardment marked the deadliest ...

U.S. fighter jets scrambled Wednesday to intercept four Russian warplanes off the coast of Alaska, the North American Aerospace Defense Command (NORAD) said Thursday. NORAD said in a statement it ...

U.S. fighter jets were scrambled Wednesday to identify and intercept four Russian warplanes flying near Alaska, the North American Aerospace Defense Command said in a statement. NORAD said two Russian ...

While the path for any drug to go from lab research to commercialization takes years, Intercept Pharmaceuticals now stands as another example that a product’s market exit can also be long and winding.

Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.

Sept 11 (Reuters) - Intercept Pharmaceuticals said on Thursday it is withdrawing its liver disease drug from the U.S. market following a request from the Food and Drug Administration. This comes as ...

After years of regulatory struggles for Intercept Pharmaceuticals and its liver disease drug Ocaliva (obeticholic acid), the FDA has called time on the drug's run in the U.S. market. The agency placed ...